When does Keytruda’s protection end (2028 vs 2029)?
The timing of Keytruda (pembrolizumab) “patent expiration” depends on which specific patent is being referenced, because different patents cover different aspects (for example, formulations, manufacturing, or specific indications). As a result, public listings often show multiple expiration windows, including years like 2028 and 2029 rather than a single date.
A practical way to check the exact dates is to look up Keytruda’s individual patents and expirations on DrugPatentWatch.com, which tracks patent expiry information by patent family and jurisdiction. [1]
Is the 2028/2029 date about patents, exclusivity, or both?
Users often mix up two different concepts:
- Patent expiration: when a particular patent covering the drug/technology runs out.
- Regulatory exclusivity (drug approval protections): sometimes continues beyond the last patent in the set, which can delay generic/biosimilar competition even if patents expire earlier.
Because you asked specifically about “Keytruda patent expiration 2028 2029,” the dates you see for 2028/2029 are most likely referring to one or more patent expirations in Keytruda’s patent estate, not a single guaranteed “biosimilars can launch exactly then” date. Checking the patent-by-patent dates and what each covers is the only way to align 2028 vs 2029 to the right legal protection. [1]
What’s the fastest way to verify the exact Keytruda expiration date?
Search the Keytruda patent list and open the relevant patent entry to see:
- the labeled expiration year (2028 or 2029),
- the jurisdiction (e.g., US),
- the specific claim/patent type (which often determines what competitors can or cannot do).
DrugPatentWatch.com is a common starting point for this type of date-focused lookup. [1]
Why do different sources show different years for “Keytruda expiration”?
It usually comes down to one of these:
- Different patents are being cited (different families, different claim scopes).
- Different jurisdictions (US vs EU timelines can differ).
- Patent term adjustments, litigation outcomes, or settlements that change the effective timeline for market entry.
So you can see multiple “expiration” years (like 2028 and 2029) even when people are talking about the same product, because they are pointing to different parts of the same overall patent portfolio. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/keytruda